ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Belatacept Immunotherapy Is Not Augmented by Blockade of Activated LFA-1 in a Nonhuman Primate Renal Transplant Model.

K. Samy,1 M. Mulvihill,1 B. Collins,1 D. Lo,2 M. Song,1 F. Leopardi,1 A. Kirk.1,2

1Department of Surgery, Duke University Medical Center, Durham, NC
2Emory University, Atlanta, GA.

Meeting: 2016 American Transplant Congress

Abstract number: B31

Keywords: Adhesion molecules, Co-stimulation, Graft survival, Primates

Session Information

Session Name: Poster Session B: Allograft Rejection, Tolerance, and Xenotransplantation

Session Type: Poster Session

Date: Sunday, June 12, 2016

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Purpose: Belatacept specifically targets de novo alloimmune responses without off target side effects. However, resistant alloreactive memory T cells have complicated its use. LFA-1 therapy has been shown to mitigate belatacept resistant rejection in islet transplantation, but at the cost of broad impairment of immune memory. Here we investigate AL579, a monoclonal antibody specific only for the high affinity conformation of LFA-1, to assess its efficacy and safety profile in renal transplantation.

Methods: Rhesus macaques underwent bilateral nephrectomy and MHC mismatched renal allograft transplantation. Control transplants received perioperative steroids with belatacept maintenance therapy, with experimental recipients receiving an additional induction course of AL579. Serial creatinine was used to monitor renal function. Longitudinal flow cytometry of peripheral blood mononuclear cells (PBMCs) was performed after transplantation. Flow cytometry was performed on lymphocytes, splenocytes, and renal graft infiltrating cells (GICs) on rejection, with lymph nodes, spleen, and allograft recovered for histology.

Results: The addition of AL579 did not improve renal allograft survival compared to belatacept based immunotherapy (Fig 1). Preliminary analysis of longitudinal PBMC phenotyping did not reveal significant differences in T memory subsets or their proliferative markers. Preliminary analysis of GICs do not suggest a different rejection phenotype when analyzing for similar parameters. Immunohistochemical and protective immunity assessments are ongoing.

Conclusions: We find that targeted inhibition of activated LFA-1 did not sufficiently mitigate belatacept resistant immune memory. The redundant effector mechanisms of alloreactive memory T cells likely circumvent highly specific inhibitory agents such as AL579. While longitudinal and endpoint immunophenotyping did not appear to identify a unique profile with AL579 adjuvant therapy, immunohistochemical analysis remains ongoing for a potential vascular adhesion/infiltration phenotype.

CITATION INFORMATION: Samy K, Mulvihill M, Collins B, Lo D, Song M, Leopardi F, Kirk A. Belatacept Immunotherapy Is Not Augmented by Blockade of Activated LFA-1 in a Nonhuman Primate Renal Transplant Model. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Samy K, Mulvihill M, Collins B, Lo D, Song M, Leopardi F, Kirk A. Belatacept Immunotherapy Is Not Augmented by Blockade of Activated LFA-1 in a Nonhuman Primate Renal Transplant Model. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/belatacept-immunotherapy-is-not-augmented-by-blockade-of-activated-lfa-1-in-a-nonhuman-primate-renal-transplant-model/. Accessed May 9, 2025.

« Back to 2016 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences